血管紧张素Ⅱ受体亚型Ⅰ拮抗剂及其临床应用
被引量:1
摘要
血管紧张素Ⅱ受体亚型Ⅰ拮抗剂及其临床应用苏哲坦综述(海南省人民医院心内科海口570311)关键词血管紧张素Ⅱ受体,ATⅠ受体拮抗剂抑制剂综述文献血管紧张素Ⅱ(AⅡ)是体内产生的强力升压物质,具有促进醛固酮和儿茶酚胺分泌,刺激血管平滑肌细胞增殖及调节肾...
同被引文献6
-
1崔吉君.高血压指南(资料连载)[J].北京军区医药,2000,12(1):18-19. 被引量:1
-
2Cohen D,Dodds R,Viberti G. Effect of protein restriction in insulin dependent diabetics at risk of nephropathy[J]. Br Med J,1987,294:795-798.
-
3Redon J. Treatment of patients with essential hypertension and microalbuminuria[J]. Drugs, 1997,54:857-866.
-
4Bremner AD,Baur M,Oddou Stock P,et al. Valsartan:long-term efficacy and tolerability compared to lisinopril in elderly patients with essential hypertension [ J]. Clin Exp Hypertens, 1997,19:1263-1285.
-
5Cifkova R,Peleska J,Hradec J,et al. Valsartan and atenolol in patients with severe essential hypertension [J]. J Hum Hypertens, 1998,12: 563-567.
-
6Mann JF. Valsartan and the kidney: present and future [ J ]. J Cardiovasc Pharmacol. 1999,33 ( Supple 1 ): S37-S40.
-
1麦炜颐,马虹.血管紧张素Ⅱ受体亚型Ⅰ拮抗剂应用的进展[J].心功能杂志,1997,9(4):229-233.
-
2苏哲担.血管紧张素Ⅱ受体亚型Ⅰ拮抗剂及其临床应用[J].中国实用内科杂志,1997,17(2):120-121. 被引量:7
-
3钱家庆.血管紧张素Ⅱ受体亚型及其阻断剂[J].中国药师,1999,2(5):240-241.
-
4余振球.掌握抗高血压药物的应用(三)[J].中国社区医师,2007,23(18):8-9. 被引量:3
-
5秦索娜.坎地沙坦的药理特性及临床研究[J].中国新医药,2004,3(7):78-80. 被引量:4
-
6朱铁梁,郝素云.他索沙坦的药理作用与临床应用[J].医药导报,2002,21(S1).